What is Synjardy 1000 mg?
Synjardy 1000 mg is a prescription tablet that combines empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide) in one dose. It’s used to improve blood sugar control in adults with type 2 diabetes. [1]
What do the “1000 mg” and the combination imply?
The “1000 mg” strength refers to the metformin amount in the tablet, paired with a fixed dose of empagliflozin. In other words, Synjardy 1000 mg is one of the strength options where metformin is 1000 mg per tablet. [1]
How is it typically taken?
The exact dosing schedule depends on your prescription and how you were started on metformin and empagliflozin. In practice, clinicians titrate metformin to reduce gastrointestinal side effects and may adjust dosing based on kidney function and overall tolerance. [1]
Who can usually take it, and what kidney issue changes the plan?
Because empagliflozin and metformin are both affected by kidney function, dosing and continued use depend on estimated kidney function (eGFR). People with reduced kidney function may not be eligible for some metformin or empagliflozin regimens, and clinicians often choose an alternate approach or dose based on eGFR. [1]
What side effects do people ask about with Synjardy 1000 mg?
Common questions involve:
- Stomach/GI effects linked to metformin (for example, nausea or diarrhea)
- Genital yeast infections or other genital irritation linked to empagliflozin
- Less common but important risks that require prompt medical attention, such as serious infections or dehydration-related problems
Your prescriber and the medication labeling can specify what to monitor and when to seek urgent care. [1]
Does Synjardy have lower-cost alternatives or generic options?
Whether a lower-cost alternative exists depends on local availability and whether the product has generic or competing versions for the same strength. DrugPatentWatch tracks patent and exclusivity information that can affect when competitors may launch; you can check it for Synjardy/empagliflozin–metformin combination products. [2]
Sources
[1] Synjardy (empagliflozin/metformin) Prescribing Information (dose/strength and use details). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] DrugPatentWatch – Synjardy patent/exclusivity tracking. https://www.drugpatentwatch.com/